

NCAB ad hoc Subcommittee on Experimental Therapeutics

Concept: Bringing together leaders who discover, develop, and finance new experimental treatments for cancer

Question: The NCI has deep expertise and resources that can accelerate bringing new experimental treatments to patients. We are not clear why more VCs who incubate new companies that discover and develop innovative experimental medicines do not engage with the NCI.

Can we build relationships between influential VCs who can build and finance new companies in order to:

- 1) Demystify the NCI so innovation capital and entrepreneurs can partner with the NCI more often
- 2) Create new discovery collaborations with NCI investigators (e.g. the RAS initiative/BridgeBio Pi3k/RAS Breaker, CRADAs)
- 3) Improve access and democratize access to the highest quality translational and discovery tools (e.g. PDX models, FLNAC, CART manufacturing, natural library HTS center, CryoEM, computational tools, etc)
- 4) License promising experimental medicines into new companies that can drive a product forward from the extramural and intramural programs (e.g. CARGO/CD22 CART)
- 5) Accelerate clinical trial times and improve patient access through NCI clinical trial sites for faster recruitment of promising phase 1 and phase 2 clinical trials, potentially registrational trials as well (certainly the case for pediatric trials with COG)

Through these efforts can we bring novel products to help patients that are waiting.


Overview of NCI Support for Advancing New Products

- 1. Advancing new therapeutics into commercial sector – getting more drugs to patients, recruitment of partners and investors**

- 2. Extramural support (Division of Cancer Treatment & Diagnosis)**
 - a. Grants – RPGs**
 - b. NExT, Stepping Stones**
 - c. SBIR/STTR (outreach in form of Webinars, Innovation Lab Podcast)**


- 3. Intramural support (Center for Cancer Research)**
 - a. NCI Technology Transfer Center (<https://techtransfer.cancer.gov/available-technologies>)**
 - b. NCI TTC Invention Development Program**
 - c. CCR Drug Development Collaborative**

Extramural Support for Discovery and Development




NExT: Discovery, Development, Clinical Testing


Chemistry Biology Consortium (**CBC**)
Focus is small-molecule drug discovery



DTP supports preclinical development and IND-enablement



Clinical Trial support using NCI **CTEP** Clinical Trials Networks



Overview of NCI Support for Advancing New Products

1. Advancing new therapeutics into commercial sector – getting more drugs to patients, recruitment of partners and investors

2. Extramural support (Division of Cancer Treatment & Diagnosis)
 - a. Grants – RPGs
 - b. NExT, Stepping Stones
 - c. SBIR/STTR (outreach in form of Webinars, Innovation Lab Podcast)

3. **Intramural support (Center for Cancer Research)**
 - a. **NCI Technology Transfer Center** (<https://techtransfer.cancer.gov/available-technologies>)
 - b. **NCI TTC Invention Development Program**
 - c. **CCR Drug Development Collaborative**

Workshop 1: Build relationships, focus on areas of overlapping priorities, and clarify how VCs might engage with the NCI

Format: Bring together a group of senior VC leaders who are actively building and investing in early stage oncology startups with the key NCI leadership with assistance of the NCAB experimental therapeutics subcommittee

Target funds: Venture Capital Funds that incubate new companies and financing emerging therapeutics in oncology. (e.g. 5AM, Arch, Atlas, Bain, Cormorant, Canaan, Deerfield, Frazier, Flagship, Omega, Orbimed, RA, Samsara, Third Rock, The Column Group, Westlake, Vida, Venbio) Each of these funds incubate 3-15 new biotech companies every 2-3 years. Historically oncology was ~60% of capital deployed.

Who: General Partner/Managing Partners or heads of incubation for the funds who are decision makers about capital allocation and internal resource deployment

Target timing: November or 1H 2025 (?)

Duration: TBD (?)

Why to attend: Access to promising assets and discovery capabilities (eg. Products, IP, computational power, tools, assays, relationships) and building relationships with leaders in cancer research



**NATIONAL
CANCER
INSTITUTE**

www.cancer.gov

www.cancer.gov/espanol